HRP20110146T1 - Derivati citokina - Google Patents

Derivati citokina Download PDF

Info

Publication number
HRP20110146T1
HRP20110146T1 HR20110146T HRP20110146T HRP20110146T1 HR P20110146 T1 HRP20110146 T1 HR P20110146T1 HR 20110146 T HR20110146 T HR 20110146T HR P20110146 T HRP20110146 T HR P20110146T HR P20110146 T1 HRP20110146 T1 HR P20110146T1
Authority
HR
Croatia
Prior art keywords
polypeptide
nucleic acid
diseases
host cell
qgp
Prior art date
Application number
HR20110146T
Other languages
English (en)
Croatian (hr)
Inventor
Hartley Oliver
Original Assignee
Mintaka Foundation For Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mintaka Foundation For Medical Research filed Critical Mintaka Foundation For Medical Research
Publication of HRP20110146T1 publication Critical patent/HRP20110146T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
HR20110146T 2006-07-25 2007-07-25 Derivati citokina HRP20110146T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0614755.7A GB0614755D0 (en) 2006-07-25 2006-07-25 Cytokine derivatives
PCT/IB2007/003026 WO2008012689A2 (en) 2006-07-25 2007-07-25 Cytokine derivatives

Publications (1)

Publication Number Publication Date
HRP20110146T1 true HRP20110146T1 (hr) 2011-06-30

Family

ID=37006114

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110146T HRP20110146T1 (hr) 2006-07-25 2007-07-25 Derivati citokina

Country Status (25)

Country Link
US (2) US8686111B2 (https=)
EP (1) EP2076532B1 (https=)
JP (1) JP5224603B2 (https=)
KR (1) KR101530353B1 (https=)
CN (1) CN101511867B (https=)
AT (1) ATE490270T1 (https=)
AU (1) AU2007278894B2 (https=)
BR (1) BRPI0715331B8 (https=)
CA (1) CA2658806C (https=)
CY (1) CY1111630T1 (https=)
DE (1) DE602007010969D1 (https=)
DK (1) DK2076532T3 (https=)
ES (1) ES2361455T3 (https=)
GB (1) GB0614755D0 (https=)
HR (1) HRP20110146T1 (https=)
ME (1) ME01320B (https=)
MX (1) MX2009000918A (https=)
NZ (1) NZ575092A (https=)
PL (1) PL2076532T3 (https=)
PT (1) PT2076532E (https=)
RS (1) RS51854B (https=)
RU (1) RU2461567C2 (https=)
SI (1) SI2076532T1 (https=)
WO (1) WO2008012689A2 (https=)
ZA (1) ZA200901342B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201600091033A1 (it) * 2016-09-08 2018-03-08 Bioimmunizer Sagl Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti.
CA3101556A1 (en) * 2018-05-28 2019-12-05 ORION Biotechnology Switzerland Sarl Ccr5 inhibitor for use in treating cancer
WO2019229615A1 (en) 2018-05-28 2019-12-05 Université De Genève Methods of inhibiting cerebral inflammation
WO2024146707A1 (en) 2023-01-06 2024-07-11 Université De Genève Variant ligand conjugates for payload delivery
WO2025172252A1 (en) 2024-02-15 2025-08-21 Novo Nordisk A/S Protracted ccr5 antagonists and uses thereof
WO2025176787A1 (en) 2024-02-22 2025-08-28 Orion Biotechnology Holding Sa Ccl5 variants for modulating gpr75
WO2025186255A1 (en) 2024-03-06 2025-09-12 Orion Biotechnology Holding Sa Gipr inhibitors and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1111540C (zh) * 1993-06-09 2003-06-18 康诺特实验室有限公司 串联的合成hiv－1肽类
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
UA77950C2 (en) 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
US20030049603A1 (en) * 2001-09-05 2003-03-13 Guy Gorochov Methods for construction and screening of libraries of chemokine variants
US7442512B2 (en) 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2005112567A2 (en) 2004-05-03 2005-12-01 University Of Maryland Biotechnology Institute Vaginal microbicide

Also Published As

Publication number Publication date
DE602007010969D1 (de) 2011-01-13
GB0614755D0 (en) 2006-09-06
HK1131162A1 (en) 2010-01-15
EP2076532B1 (en) 2010-12-01
RU2461567C2 (ru) 2012-09-20
JP5224603B2 (ja) 2013-07-03
BRPI0715331B8 (pt) 2021-05-25
US20090317363A1 (en) 2009-12-24
US9328153B2 (en) 2016-05-03
ZA200901342B (en) 2010-11-24
NZ575092A (en) 2011-08-26
DK2076532T3 (da) 2011-03-07
CA2658806C (en) 2017-01-03
KR20090060281A (ko) 2009-06-11
ME01320B (me) 2013-12-20
CN101511867B (zh) 2014-04-09
RS51854B (sr) 2012-02-29
BRPI0715331A2 (pt) 2013-07-16
CN101511867A (zh) 2009-08-19
SI2076532T1 (sl) 2011-06-30
PT2076532E (pt) 2011-03-02
PL2076532T3 (pl) 2011-07-29
WO2008012689A3 (en) 2008-05-08
ES2361455T3 (es) 2011-06-17
RU2009106436A (ru) 2010-08-27
JP2009544304A (ja) 2009-12-17
US8686111B2 (en) 2014-04-01
AU2007278894A1 (en) 2008-01-31
ATE490270T1 (de) 2010-12-15
CA2658806A1 (en) 2008-01-31
KR101530353B1 (ko) 2015-06-26
EP2076532A2 (en) 2009-07-08
BRPI0715331B1 (pt) 2021-04-13
MX2009000918A (es) 2009-08-26
CY1111630T1 (el) 2015-10-07
AU2007278894B2 (en) 2012-08-09
US20130330305A1 (en) 2013-12-12
WO2008012689A2 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
HRP20110146T1 (hr) Derivati citokina
Chang et al. Tilapia (Oreochromis mossambicus) antimicrobial peptide, hepcidin 1–5, shows antitumor activity in cancer cells
Kurschus et al. IL-17 for therapy
DE60316291D1 (de) Esterderivate von hyaluronsäure zur herstellung von hydrogelmaterialien durch photohärtung
WO2010150233A3 (en) Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
Paroli et al. The role of interleukin-17 in juvenile idiopathic arthritis: from pathogenesis to treatment
HRP20130975T1 (hr) Pripravci i postupci proizvodnje pripravaka
HRP20110368T1 (hr) Biološki aktivni proteini s povećanom stabilnošću in vivo i/ili in vitro
HRP20041108B1 (hr) Peptidi povezani sa tumorom koji se vežu na mhc molekule
KR20150022800A (ko) 악액질 예방 또는 치료용 조성물
CN103030687B (zh) 青环海蛇抗炎活性肽Hydrostatin-SN1及其编码基因和在制药中的应用
WO2018067217A3 (en) COMPOSITIONS COMPRISING SHORT PEPTIDES DERIVED FROM PEDF AND USES THEREOF
Mah et al. The ubiquitin-like modifier FAT10 is required for normal IFN-γ production by activated CD8+ T cells
CN107619437A (zh) 一种皮肤创伤修复肽whpp‑oa1及其提纯方法与应用
JP2009544304A5 (https=)
MX341317B (es) Proteinas de elastasa recombinantes y metodos de fabricacion y uso de las mismas.
Song et al. Delivery of the high-mobility group box 1 box A peptide using heparin in the acute lung injury animal models
JP2023517616A (ja) 急性呼吸窮迫症候群およびウイルス感染の治療用のｃｘｃｒ４阻害剤
HRP20140888T1 (hr) Humana monoklonalna protutijela za humani il-4
JP2017519763A5 (https=)
Il’in et al. Analysis of IL-1α, bFGF, TGF-β1, IFNγ, MMP-1, and CatD expression in multinuclea macrophages in vitro
US8815812B2 (en) Synthetic arginine substituted peptides and their use
CN102115495B (zh) 胶原靶向治疗增生性瘢痕蛋白药物的制备及应用
JP2011503008A5 (https=)
WO2023201335A3 (en) Purified multivalent protein-hyaluronic acid polymer conjugates